Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the ...

Sleep apnea is a very common health condition affecting millions worldwide. It is a risk factor for several diseases, like ...

Revolutionary weight-loss drugs are transforming U.S. health care, prompting patients to seek diagnoses for obesity-related ...

Weight-loss drugs are increasingly prescribed in the U.S., not only for obesity treatment but also to facilitate eligibility ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Sleep apnea is a sleep disorder characterized by interrupted breathing. There are two main types of sleep apnea: obstructive ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

The power of deep breathing for weight loss While seated ... Proof of the slimming power of sleep: A University of Chicago ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Sleep apnea is a sleep disorder in which breathing ... Mood changes, such as irritability or depression. • Lose weight if overweight. • Avoid alcohol and sedatives. • Sleep on your side.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...